Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers Squibb stock (NYSE: BMY) is up 15% in a month, slightly outperforming the broader S&P500 index, up 11%.

Up 15% In A Month Will Bristol Myers Squibb Stock Continue To See Higher Levels?

Shares of this pharmaceutical stock have surged higher in 2022.

Is This Blue-Chip Dividend Stock a Buy?

Amgen

These two top biopharma stocks are crushing the 2022 bear market.

2 Ultra-Safe Passive Income Stocks to Buy Right Now

Biopharma leader Bristol-Myers Squibb posted solid Q3 results, despite competition from generic-drug makers for its popular cancer pill. The post Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow appeared first on Investor's Business Daily.

Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

AbbVie

BioNTech SE

Johnson & Johnson

Eli Lilly

Moderna

Pfizer

With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting.

The 7 Best Pharma Stocks to Buy Now

Just because the stock market is going haywire doesn't mean you have to sit on the sidelines.

Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks

Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022

Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties' multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian's cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

The biopharma company has a lot riding on its new drugs.

Is Bristol Myers Squibb Stock a Buy With Its New-Product Sales Soaring?

Bristol Myers Squibb stock posts results that establish it as an attractive value stock, even if it may not be as undervalued as it appeared before.

Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value

Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.

Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y

Bristol-Myers Squibb Co (NYSE:BMY ) Q3 2022 Earnings Conference Call October 26, 2022 8:00 AM ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner - EVP & Chief Commercialization Officer Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development Conference Call Participants Giovanni Caforio - Chairman & CEO Seamus Fernandez - Guggenheim Securities Andrew Baum - Citigroup Robyn Karnauskas - Truist Securities Stephen Scala - Cowen and Company Carter Gould - Barclays Bank Luisa Hector - Berenberg Terence Flynn - Morgan Stanley Timothy Anderson - Wolfe Research Christopher Schott - JPMorgan Chase & Co. Matthew Phipps - William Blair & Company Chris Shibutani - Goldman Sachs Group Colin Bristow - UBS Mohit Bansal - Wells Fargo Securities Dane Leone - Raymond James & Associates Evan Seigerman - BMO Capital Markets Operator Good day, and welcome to the Bristol-Myers Squibb Third Quarter Results Conference Call. Today's conference is being recorded.

Bristol-Myers Squibb Co (BMY) Q3 2022 Earnings Call Transcript

BMY stock dipped Wednesday after Bristol Myers Squibb reported better-than-expected third-quarter earnings and sales. The post Bristol Myers Snags Narrow Quarterly Beat, Keeps Outlook; But Shares Fall appeared first on Investor's Business Daily.

Bristol Myers Snags Narrow Quarterly Beat, Keeps Outlook; But Shares Fall

Shares of Bristol Myers Squibb BMY, -0.30% were up 1.2% in premarket trading on Wednesday, the day after the company shared better-than-expected results for the third quarter of the year. Bristol had earnings of $1.6 billion, or 75 cents per share, in the third quarter of 2022, up from $1.5 billion, or 69 cents per share, in the same quarter in 2021.

Bristol Myers Squibb's stock is up, says Revlimid sales are declining

Sales of the company's blockbuster cancer drug Revlimid, which has faced increased competition this year, tumbled 28% in the quarter.

Bristol Myers Sales Fall on Strong Dollar. But Earnings Beat Expectations.

New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Reports Third Quarter Financial Results for 2022

Bristol Myers Squibb Reports Third Quarter Financial Results for 2022

The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program

Eli Lilly and Bristol Myers Squibb should benefit from two unique therapies.

2 Pharma Stocks With Blockbuster Drugs on the Horizon

Boeing

Kraft Heinz

The three major U.S. equity indexes closed higher on Friday, after staggering a bit in the early going.

Earnings Previews: Boeing, Bristol-Myers Squibb, Kraft Heinz

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.

Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?

New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy

News for Bristol-Myers Stock (BMY)